Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Cell-based therapy to treat heart damage: a history
- Cell types
- Chronic ischemic cardiomyopathy
- Talk outline
- Cells with cardioreparative properties
- Impact of MSCs on scar morphology
- TAC-HFT trial
- Idiopathic Dilated Cardiomyopathy (IDC)
- Ejection fraction (%)
- Cardiac function
- Low-responders vs. super-responders (1)
- Low-responders vs. super-responders (2)
- Staged surgical palliation for patients with hypoplastic left heart syndrome
- Targeting endogenous regeneration
- Activation of endogenous precursor cells by MSCs
- MSCs and cell cycle activity
- CONCERT-HF trial
- CCTRN CONCERT-HF trial: organizational structure
- CONCERT-HF trial: outcome
- Studies on mesenchymal precursor cells in patients
- DREAM-HF: summary of findings
- MSCs: impact on the vasculature (1)
- MSCs: impact on the vasculature (2)
- POSEIDON-DCM trial
- POSEIDON-DCM super-responders
- Patient genotype classification
- Genetic testing results
- Genotype modifies responsiveness of cardiac function
- Negatives for the pathologic variant have a greater improvement in QoL
- Genetic variation affects MACE and survival in response to MSC delivery
- POSEIDON-DCM 2 trial
- Mechanistic considerations
- Identification of exosomes in the sheep reticulocyte
- Identification of exosomes in the _x000B_rat reticulocyte
- Cell-cell connections
- Tunneling nanotubes
- Cell-to-cell connections
- Using hESC-CMs in non-human primates
- Transplanted iPSC-CMs
- Malignant ventricular arrhythmias
- Progress to the clinic: cell therapy
- Acknowledgements
- Disclosures
Topics Covered
- Cardiac stem cell therapy
- Adult stem cells
- Pluripotent stem cells
- Chronic ischemic cardiomyopathy
- Ventricular remodeling
- CONCERT-HF trial
- DREAM-HF trial
- Mesenchymal Stem Cells (MSCs)
- Idiopathic Dilated Cardiomyopathy (IDC)
- The POSEIDON-DCM trial
- Cell-cell connections
- Tunneling nanotubes
- Using hESC-CMs in non-human primates
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hare, J.M. (2024, July 31). Cardiac stem cell therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/NTMN8630.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Joshua M. Hare has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cell Biology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Joshua M. Hare, M.D.
I am a professor of medicine at
the Miller School of Medicine
at the University of Miami.
Today, I'm going to
speak to you about
cardiac stem cell therapy.
0:16
There has been a
long-standing quest to repair
the damaged heart with
cell-based therapy
that goes back to the 1990s,
at which time there were
early attempts using
skeletal myoblasts to repair
damaged hearts in
preclinical models.
In the early 2000s, investigators
turned their interest
to answering the question
of whether tissues like
the bone marrow contain
a compartment of cells with
tissue reparative properties.
Since that time there's been
an extensive amount
of work using
adult type cell-based therapy
from bone marrow and
other types of tissues.
But this has been accompanied
by very substantial controversy
over whether such cells
have true differentiation
capacity.
In other words, can
these cells engraft and
differentiate into a host
tissue like the heart?
This field however has
continued to produce
provocative data and there
are ongoing clinical
trials to this date.
The current state of
the art in the 2020s
is to explore programs
that have developed
on the earlier work
that use, for example,
combination cell
therapy, combining
different types of cells
to optimize a result,
combining cell with gene therapy
and finally, we are starting to
see the clinical development
of pluripotent stem cells,
again alone or in combination.
I will cover each of these
topics in the lecture.
Another approach
that I won't cover
in this lecture is
whether or not we can
improve tissue repair by using
tissue engineering approaches
as compared to just
cell-based therapy alone.
But the topic for today is
cell-based therapy alone.